WHAT YOU NEED TO KNOW
  • Denmark recorded 9.9 RSV hospitalizations per 1,000 babies ages 0 to 5 months, down from a previous average of 39.3.
  • A meta analysis found maternal RSV vaccination was 73.6% effective at preventing hospitalization among babies younger than 6 months.
  • Vaccination during pregnancy and long acting antibodies provide two approaches for protecting infants during their earliest months.
  • Modeling found 90% antibody coverage could prevent 61% of RSV hospitalizations among babies ages 0 to 2 months.

Prevention programs targeting respiratory syncytial virus, or RSV, have delivered striking results, with studies documenting sharp declines in infant hospitalizations after immunization campaigns began. Evidence from Denmark, Spain, and the UK, along with a broader analysis, points to major protection during babies’ earliest months.

Denmark introduced RSV vaccination for pregnant people in 2025. The subsequent surveillance pattern was so unexpected that a colleague suggested to epidemiologist Caroline Klint Johannesen that an error must have occurred.

Johannesen and colleagues wrote, “During the 2025-26 season RSV surveillance data from Denmark show a clear deviation from the expected epidemic curve.” The figures showed how dramatically the hospitalization pattern had changed.

Previously, the average incidence of RSV associated hospitalizations among babies ages 0 to 5 months was 39.3 per 1,000. By late April 2026, Denmark was recording only 9.9 hospitalizations per 1,000.

Promising results have also emerged in other countries and regions. One study involving hospitals in Spain and the UK found respective reductions of 55% and 18% in RSV associated hospitalizations after prevention programs were introduced.

A recent meta analysis found encouraging evidence concerning the effectiveness and safety of maternal RSV vaccination. Its pooled results showed vaccine effectiveness of 73.6% in preventing hospitalization among babies younger than 6 months.

RSV commonly causes symptoms resembling a cold, and most people have encountered it by age 2 without serious adverse effects. The infection can be deadly, however, for very young babies, children born prematurely, and those with serious health conditions.

After six decades of research, an RSV vaccine received approval from the US Food and Drug Administration in 2023. Older adults, who also face a higher risk of complications, were the first group targeted.

Do you read nutrition labels before buying packaged foods?

By completing the poll, you agree to receive emails from Being Healthy News, occasional offers from our partners and that you've read and agree to our privacy policy and legal statement.

The phase 3 trial showed that the vaccine reduced the risk of severe illness by more than 94% among adults over 60. Vaccination during pregnancy was introduced soon afterward to help protect infants during the crucial first months of life.

Long acting antibodies offer another way to protect newborns. Instead of training the immune system to respond to RSV, this approach directly provides protective antibodies while a baby’s immune system matures.

Antibody immunization may be used when vaccination during pregnancy did not occur or when a baby was born very soon after maternal vaccination. Treatment is generally timed for the winter virus season, when infections reach their peak.

Data published in September 2026 indicated that preventive antibodies remained effective. Scientists examined RSV genetic sequences from around the world and found that variants resistant to the available antibodies were rare.

“It's so incredible as a pediatrician, and as a mom, that we now have these prevention tools for RSV,” first author Dr Cassandra Simonich said in a statement. Recommendations and access for vaccination and antibody immunization differ around the world.

The UK National Health Service currently offers RSV vaccination from week 28 of pregnancy, to people ages 75 and older, and to adults ages 65 to 74 with certain long term conditions. In the US, the American Medical Association included RSV vaccines in its recent winter vaccine recommendations.

The American Medical Association and other medical experts issued guidance separate from the Centers for Disease Control and Prevention’s guidelines, representing a historic break with tradition. An analysis of 75 earlier studies concluded that maternal vaccination and vaccines for older adults effectively reduced severe disease and hospitalization.

Most infant deaths from RSV occur in low and middle income countries. A multidose maternal vaccine could improve access because one vial can immunize several people with a new sterile needle used each time, while also reducing transportation costs and storage needs.

Vaccines require constant refrigeration, and maintaining that cold chain can be difficult in lower income settings and remote areas. The World Health Organization approved a multidose RSV vaccine, which Gavi Senior Policy Manager Ignacio Esteban called a “key milestone.”

Gavi, The Vaccine Alliance, is supporting a vaccine rollout. Modeling from the European Centre for Disease Prevention and Control found that 90% coverage with long acting antibodies could prevent 61% of RSV related hospitalizations among babies ages 0 to 2 months.

The same assessment found that 90% coverage with maternal vaccination could avert 52% of hospitalizations. ECDC Head of Unit Bruno Ciancio said, “Protecting infants from RSV in the first months of their life is particularly important, and we have a tool to do just that.”